ArticleCurrent oncology (Toronto, Ont.)2021
Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review.
Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.BMC pharmacology & toxicology · 2026Trial
- A randomized clinical trial assessing the efficacy of vitamin B prophylaxis in attenuating paclitaxel-induced neuropathy and the imperative use of gabapentin in diabetic ovarian cancer patients.Medical oncology (Northwood, London, England) · 2026Trial
- Incidence and associated factors of falls in patients with chemotherapy-induced peripheral neuropathy: a scoping review and evidence mapping.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Quantitative sensory testing and skin biopsy for neuropathy assessment in Portuguese patients with type 1 diabetes: an exploratory study.Endocrine · 2025Article
- Adverse Reactions to Taxanes in Premedicated Cancer Patients: A Prospective Observational Study.Cureus · 2025Article
- Neurotoxicity associated with cancer chemotherapy: the first study in the Palestinian healthcare system.BMC cancer · 2025Article
- Transcranial magnetic stimulation measures of corticospinal excitability in Black and Hispanic/Latino people with painful peripheral neuropathy.Frontiers in human neuroscience · 2025Article
- Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review.Journal of clinical medicine · 2024Review
- Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Breast cancer insights from Northern Israel: a comprehensive analysis of survival rates among Jewish and Arab women.Frontiers in oncology · 2024Article
- Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Observational
- SymptomGraph: Identifying Symptom Clusters from Narrative Clinical Notes using Graph Clustering.Proceedings of the ... Symposium on Applied Computing. Symposium on Applied Computing · 2023Article
- Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study.Cancers · 2023Article
- Salivary gland cancers in elderly patients: challenges and therapeutic strategies.Frontiers in oncology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight articles fulfilled the criteria, and four more articles were retrieved from the references of the selected articles. The analysis of the studies covered the information about neuropathy recorded in 768 cancer patients with diabetes and 5247 control cases (non-diabetic patients). The drugs investigated are chemotherapy drugs with high potential to induce neuropathy, such as platinum derivatives and taxanes, which are currently the mainstay of treatment of various cancers. The predisposing effect of co-morbid diabetes on chemotherapy-induced peripheral neuropathy depends on the type of symptoms and drug used, but manifest at any drug regimen dosage, although greater neuropathic signs are also observed at higher dosages in diabetic patients. The deleterious effects of chemotherapy on diabetic patients seem to last longer, since peripheral neuropathy persisted in a higher proportion of diabetic patients than non-diabetic patients for up to two years after treatment. Future studies investigating the risk of developing peripheral neuropathy in cancer patients with comorbid diabetes need to consider the duration of diabetes, cancer-induced neuropathic effects per se (prior chemotherapy administration), and the effects of previous cancer management strategies such as radiotherapy and surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.